As such, the Company has initiated the final IND-enabling steps, including GMP manufacturing, GLP toxicology, and preparation of a pre-IND data package for the US FDA and foreign counterparts. The candidate, named ARC-520, is an RNAi therapeutic actively targeted to the liver using the company's Dynamic Polyconjugate (DPC) delivery system and includes two siRNA sequences targeting two different regions of the HBV genome.
Demyelinaing lesions show up on T2, FLAIR, PD and STIR sequences. After GAD contrast, lesions may show up on T1 sequences if they are less than about 40 days old.
If you have lesions showing up on T1 post-GAD, these are active lesions. It might be best to post the actual radiologists reports. There are several nuances to understanding what the actual reports really mean.
1. No acute findings are identified. Specifically, there is no evidence of mass effect or midline shift. There are no abnormal extraaxial fluid collections. There is no abnormal enhancement on the postcentrast sequences. There is no evidence of restricted diffusin on the diffusion-weighted sequence to suggest an acute ischemic event.
2. There is a small amount of increased periventricular T and FLAIR signal which is nonspecific but most likely related to chronic small vellel ischemic change.
After that subsided, My right arm started to have the painful spasms. I went back to the doctor for my 1 year follow up and had a new MRI. The MRI showed "Diffuse T2 prolongation within the subarachnoid space diffusely on FLAIR sequences." I have had new bloodwork and an additonal MRI done. I am now waiting for my next appointment, but wanted to get some feedback as to what other may have expeienced. Any info would be greatly appreciated.
1. There is relative increased signal seen in the upper five cervical vertebral bodies including the odontoid with low signal seen in the vertebral body of C7-T1 and T2.
2. There are posterolateral hypertrophic changes seen at the level on the invertebral plate of C4-C5 w/ no significant encroachment seen upon the fecal sac at these levels.
3.
Arrowhead Completes Enrollment in Phase 1 Study of ARC-520 for the Treatment of Chronic Hepatitis B
- Safety and tolerability support advancement of ARC-520 into Phase 2a
PASADENA, Calif. - October 8, 2013 - Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced that it has initiated a Phase 1/2 clinical trial with ALN-HBV, a subcutaneously administered investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in chronic HBV patients.
Hepatitis B virus-specific nucleic acid sequences and proteins have been detected in extrahepatic tissues of acutely and chronically infected patients. However, apart from peripheral blood mononuclear cells and bone marrow cells, little is known about the specific cell types that permit viral replication.
GAD should not show up hypointense (black) of post-contrast T1 sequences GAD will show hyperintense (bright) in T1 sequences for "active" demyelinating lesions that show up as hyperintese on T2 and FLAIR sequences. GAD only helps determine the age of an MS lesion.
There are "black holes" (gliosis) that show up on T1 sequences, but they should look the same, pre and post GAD. None of us are radiologist so this may or may not help you.
For those who take mealtime insulin, blood sugars have a tendency to rise in 1-2 hours and then drop over the next couple of hours. This is because the insulins we inject are much slower than the insulin the body makes, and also because people with diabetes lack hormones that slow the rate of digestion.
The answer, as you alluded to, is not usually to take MORE insulin. Rather, we need to either make the insulin work earlier or make the food work later. This can be accopmlished by:
A.
From the above:
"HCV is an enveloped virus with an RNA genome of approximately 9400 bp in length....HCV is classified in the family Flaviviridae, although it is differs in many details of its genome organization from the original (vector-borne) members of the family. HCV is additionally distinct and somewhat unusual for an RNA virus in being able to establish persistent infections in the majority of exposed individuals.
There were some abnormal areas seen in your brain that might be caused by blood pressure/circulation issues ("ischemic changes") or demyelination (MS is a demyelinating disease, but there are several others). These are included in the "differentials" which are essentially the radiologist's best guesses as to the cause of what they saw. It will be up to your neurologist to narrow it down based on your full clinical picture (your history, lab results, clinical exams, etc.
5 Tesla magnet, sagittal T1, sagittal T2, sagital STIR, and axial T2-weighted sequences of the cervical spine were preformed.
COMPARISON: None.
FINDINGS: The cervicomedullary junction is unremarkable.There is no signal alteration within the spinal cord.There is preservation of vertebral body height and alignment without evidence of signal alteration or acute abnormality.
At C2-C3, there is mild disc desiccation.
http://hepatitis.about.com/od/questions/f/genotype_HCV.htm
This is a link you might find helpful and following is cut/pasted:
"The hepatitis C virus (HCV) has at least six distinct genotypes, which are just different sequences of the virus's DNA, which are identified by a number. These six genotype sequences are enough alike to be a hepatitis C virus, but have enough small differences between them to be organized into six different groups.
cotrrection T1 &T2 are MRI sequences. Not MS sequences. Not specific to MRI scans for MS lesions..
Another thing to look for is T2* or T2* GRE sequences. These are gradient echo sequences. There are some studies that suggest the T2* sequences pick up more lesions than T2W. Almost all 3 T machines will need to use T2* sequences to limit the patients exposure to radio frequency and magnetic fields during exams.
Recommended
